Singapore quietly rewrote its software rules. Here's what changed.

Singapore has a reputation among founders as the tidy, English-language, common-law gateway to Asia — and then, on closer inspection, as a market whose device rules are fiddly enough to sit at the bottom of the to-do list behind the EU and the US. Both halves of that reputation are now out of date. Over the past nine months the Health Sciences Authority has revised the core software guideline, published a second edition of its AI-in-healthcare guidance, and opened reliance pathways that materially change the cost of entry.

Here is what actually changed, and how to use it.

GL-04 is the document that binds you — not the AI guidelines

This is the distinction that trips teams up. Singapore now has two documents that both talk about software and AI, and they do very different jobs.

Don't build an "AIHGle 2.0 dossier". There isn't one to build. The mistake is to treat the AI guidelines as a compliance checklist and the software guideline as background reading. It's the other way around: GL-04 is the requirement; AIHGle 2.0 is the philosophy behind it.

The change-management pathway is the quiet win

The most useful thing in the refreshed GL-04, for anyone shipping a learning or frequently-updated product, is the streamlined pathway for software changes under a change management programme. In spirit it is Singapore's answer to the FDA's predetermined change control plan and the MDR's change-control expectations: define your change envelope up front, and updates that fall inside it don't each trigger a fresh submission.

If you are already building a PCCP for the FDA, you are most of the way to satisfying this. The underlying discipline — a bounded, pre-specified, validated set of permissible changes with acceptance criteria — is the same. Write it once, format it three ways.

Reliance: the route that can halve your Singapore timeline

Singapore has long operated abridged evaluation routes that give credit for prior approvals from trusted reference regulators (the EU, US FDA, Australia's TGA, Health Canada, Japan). In 2026 HSA has widened the reliance landscape further, including a regulatory reliance arrangement with Malaysia's Medical Device Authority that lets a device registered in one country take an abbreviated route in the other.

The strategic implication is simple and often missed: the order in which you approach your markets changes your Singapore cost. A device that already holds a CE mark or FDA clearance is not starting from zero in Singapore — it is a candidate for an abridged evaluation, with a shorter queue and a smaller evidence ask. Sequencing Singapore after your first major approval, rather than in parallel from scratch, can be the difference between a full and an abridged route.

One deadline worth putting in the calendar

HSA confirmed its Registration Support Initiative on 28 August 2026. It targets devices currently supplied through the Special Access Route: essential, life-saving Class C and D devices for rare clinical situations, and legacy devices with no registered alternative. Eligible devices have their evaluation fees waived. The window matters:

If you supply a device through the Special Access Route, 31 December 2026 is the near-term action. Confirm eligibility against HSA's criteria first — the scheme is targeted, not universal.

Where the funding actually sits

A point we make often, because it saves founders months: Singapore's headline health-innovation money largely flows to institutions, not companies. The NHIC and NMRC instruments are awarded to public hospitals and research institutions with a clinician principal investigator. Your access route is a clinical partnership, not an application form — so if Singapore is on your map for grants as well as market access, pick the institution first and build the relationship, rather than hunting for a company-facing grant that mostly isn't there.

The one genuinely cross-border instrument that funds a company directly and spans both Europe and Singapore is Eurostars — worth a separate look if you are building a Europe–Singapore consortium.

The one-line version: GL-04 is what you comply with, AIHGle 2.0 is how HSA thinks, the change-management pathway mirrors your FDA PCCP, and reliance means your Singapore cost depends on which market you cleared first.

What to do this quarter

01 · Map your route against reliance

If you already hold a CE mark or FDA clearance, check whether you qualify for an abridged evaluation before scoping a full submission. It changes the timeline and the evidence ask.

02 · Reuse your PCCP as a change-management programme

The change envelope you built for the FDA maps closely onto GL-04's streamlined software-change pathway. Reformat, don't rebuild.

03 · Check the Registration Support Initiative window

If you supply a device via the Special Access Route, check it against the eligibility criteria before the inaugural window closes on 31 Dec 2026.

04 · For funding, pick the institution

Don't chase company-facing grants that mostly go to hospitals. Identify the clinical partner and PI first; the funding route follows the relationship.

Sources & further reading

1. HSA — Digital Health / Software Medical Devices (GL-04).
2. Baker McKenzie — Singapore: HSA provides medical device regulatory updates (Jun 2026).
3. Baker McKenzie — MOH and HSA launch refreshed AI in Healthcare Guidelines (AIHGle 2.0).
4. Qualtech — Singapore HSA regulatory updates: software MD, AI guidelines, MDA reliance (May 2026).
5. Baker McKenzie — Singapore: Registration Support Initiative for unregistered medical devices (Sep 2026).

This article is general information current as at 2 October 2026, not regulatory or legal advice. HSA guidance and scheme windows change; confirm the current position and your device's eligibility before acting.